Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

EP: 1.Understanding Cancer Changes and Testing: How Testing Guides Your Metastatic Breast Cancer Treatment

EP: 2.Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

EP: 3.Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

EP: 4.EMERALD Trial Results: What Prior CDK4/6i Duration Means for Treatment Success

EP: 5.Managing Elacestrant Treatment: From Patient Selection to Supportive Care

EP: 6.Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations

Now Viewing

EP: 7.Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer

Video content above is prompted by the following:

Clinical Brief: Implementation and Patient Support Strategies

Main Discussion Topics:

• Role of multidisciplinary care team in patient education and support
• Importance of early intervention for side effect management
• Strategies for ensuring medication adherence with oral therapy
• Value of nurse coordinators and pharmacist integration
• Flexible approaches, including chemotherapy-endocrine therapy sequencing

Key Points for Physicians:

• Team-based approach crucial for successful oral therapy management
• Early touchpoints in first month prevent long-term discontinuation
• Patient education impacts adherence and anxiety management
• Consider short-course chemotherapy followed by endocrine therapy in select cases
• Communication protocols essential for optimal outcomes

The discussion highlighted that successful implementation of oral targeted therapies requires comprehensive support systems and proactive communication strategies to ensure optimal patient outcomes and treatment adherence.